Mostrar el registro sencillo del ítem

dc.contributor.authorGranados Betancort, Elena
dc.contributor.authorSánchez Díaz, Manuel
dc.contributor.authorMuñoz Barba, Daniel
dc.contributor.authorArias Santiago, Salvador Antonio 
dc.date.accessioned2024-09-11T10:23:09Z
dc.date.available2024-09-11T10:23:09Z
dc.date.issued2024-08-16
dc.identifier.citationGranados-Betancort, E.; Sánchez-Díaz, M.; Muñoz-Barba, D.; Arias-Santiago, S. Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review. J. Clin. Med. 2024, 13, 4844. https://doi.org/10.3390/jcm13164844es_ES
dc.identifier.urihttps://hdl.handle.net/10481/94339
dc.description.abstractBackground: Bullous pemphigoid (BP) is an autoimmune disease characterized by the appearance of very pruritic subepidermal blisters. It appears mostly in the elderly and is associated with multiple comorbidities, which makes its management and treatment difficult. The purpose of this systematic review is to compile current information on published cases of BP treated with omalizumab (omalizumab) and dupilumab (dupilumab) in order to obtain information on clinical efficacy and safety data available. Methods: A literature search of all cases of BP treated with omalizumab/dupilumab published in the literature up to January 2024 was performed using the Pubmed database. After an exhaustive search, a total of 61 studies encompassing 886 patients met the inclusion criteria and were included in the review. Results: The majority of patients with BP treated with omalizumab/dupilumab presented a significant improvement in symptomatology, being very safe drugs with minimal side effects. The main limitation of the presented review is the quality of the included studies, most of them being case series or individual cases. The development of studies with a higher level of scientific evidence in the near future would be of great interest. Conclusions: Both omalizumab and dupilumab appear to be effective options for treating BP in patients refractory to other pharmacological therapies. They are drugs with a good safety profile and the adverse reactions associated with their use are infrequent and generally mild.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectBullous pemphigoides_ES
dc.subjectOmalizumabes_ES
dc.subjectDupilumabes_ES
dc.titleOmalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Reviewes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/jcm13164844
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional